Valuation: Viatris Inc.

Market Cap 20.18B 17.64B 16.27B 15B 28.27B 1,944B 28.9B 195B 76.51B 952B 75.79B 74.13B 3,277B P/E 2026 *
74.3x
P/E 2027 * 27.4x
Enterprise Value 32.37B 28.29B 26.1B 24.06B 45.35B 3,117B 46.35B 312B 123B 1,527B 122B 119B 5,255B EV / Sales 2026 *
2.19x
EV / Sales 2027 * 2.08x
Free-Float
92.23%
Yield 2026 *
2.94%
Yield 2027 * 3.01%
1 day+0.42%
1 week+2.72%
Current month+8.31%
1 month+8.27%
3 months+29.50%
6 months+36.89%
Current year+44.06%
1 week 14.01
Extreme 14.014
15.13
1 month 13.21
Extreme 13.212
15.13
Current year 10.49
Extreme 10.49
15.13
1 year 7.51
Extreme 7.512
15.13
3 years 6.26
Extreme 6.262
15.13
5 years 6.26
Extreme 6.262
15.13
10 years 6.26
Extreme 6.262
15.5
Manager TitleAgeSince
Chief Executive Officer 63 01/04/2023
Director of Finance/CFO 59 08/05/2026
Chief Tech/Sci/R&D Officer - 15/12/2023
Director TitleAgeSince
Director/Board Member 78 16/11/2020
Director/Board Member 78 16/11/2020
Director/Board Member 62 16/11/2020
Change 5-day change 1-year change 3-year change Capi.($)
+0.42%+2.72% - - 20.18B
+0.71%-0.79%+54.85%+163.72% 1,043B
+1.21%-1.62%+55.12%+58.94% 602B
+0.91%+3.65%+34.34%+90.70% 449B
+0.78%-0.71%+30.04%+24.61% 327B
+1.41%+0.58%+33.92%+47.20% 279B
-0.27%-1.87%+22.13%+23.47% 264B
-1.51%+1.10%+23.18%+61.24% 201B
-0.63%+4.65%+24.88%+75.35% 169B
-0.10%+3.87%+2.14%-29.99% 143B
Average +0.25%-0.68%+31.18%+57.25% 386.34B
Weighted average by Cap. +0.54%-1.82%+40.29%+84.87%

Financials

2026 *2027 *
Net sales 14.77B 12.91B 11.91B 10.98B 20.7B 1,423B 21.16B 142B 56.01B 697B 55.48B 54.27B 2,399B 15.04B 13.14B 12.13B 11.18B 21.07B 1,448B 21.54B 145B 57.01B 709B 56.47B 55.23B 2,442B
Net income 13M 11.36M 10.48M 9.66M 18.21M 1.25B 18.61M 125M 49.27M 613M 48.81M 47.74M 2.11B 498M 435M 401M 370M 697M 47.91B 713M 4.8B 1.89B 23.47B 1.87B 1.83B 80.78B
Net Debt 12.19B 10.65B 9.83B 9.06B 17.07B 1,174B 17.45B 117B 46.2B 575B 45.77B 44.76B 1,979B 11.03B 9.64B 8.9B 8.2B 15.45B 1,062B 15.8B 106B 41.82B 520B 41.43B 40.52B 1,791B
Logo Viatris Inc.
Viatris Inc. is a global healthcare company. The Company markets branded and generic drugs, including complex drugs. The Company's segments include Developed Markets, Greater China, JANZ, and Emerging Markets. Its Developed Markets segment comprises its operations primarily in North America and Europe. The Company's Greater China segment includes its operations in mainland China, Taiwan and Hong Kong. The Company's JANZ segment consists of its operations in Japan, Australia and New Zealand. Its Emerging Markets segment encompasses its presence in more than 125 countries with developing markets and emerging economies including in Asia, Africa, Eastern Europe, Latin America and the Middle East as well as the Company's ARV franchise. It produces medicines for patients across a broad range of major therapeutic areas. From cardiovascular health to oncology, it offers treatment options across more than 10 major therapeutic areas covering a variety of noncommunicable and infectious diseases.
Employees
30,000
Date Price Change
16/07/26 15.13 +5.07%
15/07/26 €14.40 +1.59%
14/07/26 €14.17 -1.25%
13/07/26 €14.35 +1.31%
10/07/26 €14.16 -3.82%
Trader
Investor
Global
Quality
ESG MSCI
A
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
10
Last Close Price
17.33USD
Average target price
17.81USD
Spread / Average Target
+2.78%

Quarterly revenue - Rate of surprise